Viridian Therapeutics, Inc.\DE 8-K

What Happened

• Viridian Therapeutics announced on June 26, 2026 that the U.S. Food and Drug Administration approved Lumvoa™ (veligrotug‑vvze) for the treatment of thyroid eye disease (TED) regardless of activity or duration. The company filed a Current Report on Form 8‑K (furnished June 29, 2026) including a press release about the approval.
• Viridian says Lumvoa is the first approved TED treatment with labeling that includes data for both active and chronic TED, and the company plans to launch Lumvoa immediately.

Key Details

• Approval date announced: June 26, 2026; 8‑K filed June 29, 2026.
• Product: Lumvoa™ (veligrotug‑vvze) for treatment of thyroid eye disease (TED) regardless of activity or duration.
• Company action: Plans an immediate commercial launch; press release furnished as Exhibit 99.1 to the 8‑K.
• Disclosure: 8‑K includes forward‑looking statements and references risk factors in Viridian’s Form 10‑Q for the quarter ended March 31, 2026 (filed May 5, 2026).

Why It Matters

• FDA approval and an immediate launch expand Viridian’s ability to generate revenue from a newly approved product and may broaden the treated patient population because the label covers both active and chronic TED.
• The filing contains no financial projections; investors should note the company’s forward‑looking statements and review Viridian’s recent SEC filings (including the May 5, 2026 10‑Q) for risk factors and additional context on commercialization plans and potential financial impact.